Docetaxel: An active drug for squamous cell carcinoma of the head and neck

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1672-1678

  Dreyfuss, A I ^a   Clark, J R ^a   Norris, C M ^a   Rossi, R M ^a   Lucarini, J W ^a   Busse, P M ^a   Poulin, M D ^a   Thornhill, L ^a   Costello, R ^a   Posner, M R ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG RESPONSE; EDEMA; FATIGUE; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 9244261066     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1672     Document Type: Article

References (37)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45:8-30, 1995
2. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
3. Dimery IW, Hong WK: Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85:95-111, 1993
4. Munro AJ: An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Brit J Cancer 71:83-91, 1995
5. Robert F, Wheeler RH, Molthrop DC, et al: Phase II study of topotecan in advanced head and neck cancer: Identification of an active new agent. Proc Am Soc Clin Oncol 13:281, 1994 (abstr 905)
6. Buesa JM, Fernandez R, Esteban E, et al: Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann Oncol 2:151-152, 1991
7. Liu JM, Chan WK, Chi KH, et al: Preliminary report of a phase II trial of ifosfamide in patients with advanced stage nasopharyngeal carcinoma in Taiwan. Proc Am Soc Clin Oncol 13:285, 1994 (abstr 923)
8. Forastiere AA, Neuberg D, Taylor SG IV, et al: Phase II evaluation of Taxol in advanced head and neck cancer: An Eastern Cooperative Oncology Group trial. Monogr Natl Cancer Inst 15:181-184, 1993
9. Forastiere AA: Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 21:49-52, 1994 (suppl 8)
10. ®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:533-537, 1994
11. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
12. Extra JM Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
13. Tomiak E, Piccart MJ, Kerger J, et al: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis J Clin Oncol 12:1458-1467, 1994
14. Burris H, Irvin R, Kuhn J, et al: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 11:950-958, 1993
15. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of taxotere. J Natl Cancer Inst 84:1781-1788, 1992
16. Bissett D, Setanoians A, Cassidy J, et al: Phase I and pharmacokinetic study of taxotere (RP56976) administered as a 24 hour infusion. Cancer Res 53:523-527, 1993
17. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
18. Francis PA, Rigas JR, Kris MG, et al: Phase II study of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
19. Fossella FV, Lee JS, Shin DMK, et al: Phase II study of docetaxel for advanced or metastatic platinum refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
20. Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
21. Piccart MJ, Gore M, Huinink WTB, et al: Docetaxel: An active drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87:676-681, 1995
22. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995
23. ®) and cisplatin against human tumor and normal bone marrow cells. Anticancer Res 14:205-208, 1994
24. ®) in head and neck squamous cell sarcinoma xenograft. Cancer Lett 81:151-154, 1994
25. Hill BT, Whelan RDH, Shellard SA, et al: Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12:169-182, 1994
26. Kelland LR, Abel G: Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450, 1992
27. Bissery MC, Guénard D, Guéritte-Voegelein F, et al: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991
28. Harrison SD Jr, Dykes DJ, Shepherd RV, et al: Response of human tumor xenografts to Taxotere. Proc Am Assoc Cancer Res 33:526, 1992 (abstr 3144)
29. Nicoletti MI, Lucchini V, D'Incalci M, et al: Comparison of paclitaxel and docetaxel activity of human ovarian carcinoma xenografts. Eur J Cancer 30A:691-696, 1994
30. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991
31. Aapro M, Braakhuis B, Dietel M, et al. Superior activity of Taxotere (Ter) over Taxol (Tol) in vitro. Proc Am Assoc Cancer Res 33:516, 1992 (abstr 3086)
32. Hanauske AR, Degen D, Hilsenbeck SG, et al: Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 3:121-124, 1992
33. Vogel M, Hilsenbeck SG, Depenbrock H, et al: Preclinical activity of Taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumor cells: Comparison with Taxol and conventional antineoplastic agents. Eur J Cancer 29A:2009-2014, 1993
34. Riou JF, Petitgenet O, Combeau C, et al: Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc Am Assoc Cancer Res 35:385, 1994 (abstr 2292)
35. ™). Ann Oncol 4:610-611, 1993
36. Jacobs C, Lyman G, Velez-Garcia E, et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257-263, 1992
37. Dreyfuss AI, Clark JR, Wright JE, et al: Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 112:167-172, 1990